Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
Biodistribution and Localization of Iodine-131 Labeled Metuximab in Patients with Hepatocellular Carcinoma
Zheng Zhang, Huijie Bian, Qiang Feng, Li Mi, Tingshu Mo, Anren Kuang, Tianzhi Tan, Yunchun Li, Wusheng Lu, Yang Zhang, Min Zhang, Rong Tian, Zhinan Chen and Ping Zhu
volume 5 | issue 3
march 2006Pages: 318-322
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
PURPOSE: Radioimmunotherapy may improve the outcome of hepatocellular carcinoma(HCC) patients by delivering targeted radiation to liver lesion tissue while relatively sparing nontarget tissues. This study was designed to observe the biodistribution, localization and imaging characteristics of 131I -labeled Metuximab in 24 patients with HCC to determine the diagnositic and therapeutic potential of this antibody. METHODS: 24 HCC patients were randomly divided into three groups to receive 18.5, 27.75 and 37 MBq/kg of 131I-labeled Metuximab per kilogram of body weight, respectively. 99mTc-sodium phytate was administered intravenously and the single photon emission computed tomography ?SPECT) scanning was performed. After 48 h, Iodine-131 labeled Metuximab was injected by hepatic artery intubation, and SPECT scan performed at 7d. The percentage of absorbed 131I (?ID) and the time-dependent 131I tumor:non-tumor tissue (T/NT) ratios were calculated at 12, 48, 96 and 192h after injection. RESULTS: The positive Imaging result of MAb scanning in 24 patients showed that the iodine 131 conjugated to Metuximab was apparently accumulated more in hepatoma. Biodistribution studies of 131I-Metuximab in trial I demonstrated that the comparable %ID uptake in tumor (with a T/NT ratio at 12, 48, 96 and 192h) to that in such normal organs, as thyroid, heart, lung, spleen and intestines were all more than 1. The optimal imaging time for the highest T/NT ratio in liver was at 192h. CONCLUSION: 131I-labeled Metuximab could delivere relatively selective radiation to tumor tissues and may have potential efficacy in relieving hepatocellular carcinoma.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.